Lipocine shifts fo­cus to CNS; Drug ap­proval trig­gers cap­i­tal in­fu­sion at Fen­nec

Lipocine, af­ter a years­long quest to snag FDA ap­proval for its oral testos­terone drug, has de­cid­ed to shift fo­cus to cen­tral ner­vous sys­tem dis­or­ders.

The Salt Lake City biotech of­fered up the new vi­sion Mon­day morn­ing in what CEO Ma­hesh Pa­tel says will al­low the com­pa­ny to “man­age our re­sources ef­fi­cient­ly.”

Lipocine will con­tin­ue fo­cus­ing on oral drugs, this time with en­doge­nous neu­roac­tive steroids (NAS) that it hopes can treat var­i­ous CNS con­di­tions. This comes half a year af­ter its oral testos­terone re­place­ment ther­a­py for hy­pog­o­nadism was ap­proved, fol­low­ing mul­ti­ple FDA snags, and is be­ing mar­ket­ed by li­cense-hold­er and com­mer­cial­iza­tion part­ner Antares Phar­ma. Lipocine still seeks an ex-US com­mer­cial­iza­tion leader.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER